Medicus Pharma Provides Interpretation of Positive Phase 2 SkinJect™ Dataset
The Company Reported 73% Clinical Clearance in the 200-µg cohort at Day 57
A Digital Publication for the Practicing Medical Specialist, Industry Executive, & Investor
The Company Reported 73% Clinical Clearance in the 200-µg cohort at Day 57